ANTIMICROBIAL RESISTANCE SOLUTIONS
WITH DR. JOHN H. REX
Latest Newsletters
Latest Government Action





















R&D Insight
Can you help?
Antimicrobial resistance poses a catastrophic threat. If we don’t act now, any one of us could go into hospital in 20 years for minor surgery and die because of an ordinary infection that can’t be treated by antibiotics. And routine operations like hip replacements or organ transplants could be deadly because of the risk of infection.
Dame Sally Davies Tweet
New mechanisms for antibiotic reimbursement in the United States: CMS’s IPPS FY2020 Final Rule
IDSA White Paper on developing narrow-spectrum antimicrobials + editorial by G. Drusano
Draft EMA antibacterial guidance: Analysis
What does an antibiotic cost to develop? What is it worth? How to afford it?
Modeling the value of an effective antibiotic — Megiddo et al.
Assessing antibiotic value: DTR, fire extinguishers, and a view from Australia
How hard (and how) to Pull? Net value of Pull via a Transferrable Exclusivity Extension (TEE)
Two new oral drugs for gonorrhea!
News from Davos 2020: Some positive signs, but overall a fragile antibiotic market at a tipping point
FDA Workshop: Animal Models To Support Antibacterial Development (5 Mar 2020, post-meeting notes)
FDA workshop: Insights on inhaled antifungals and antibacterials
NIAID workshop: What is a robust PK-PD package?
The thoughtless person playing with penicillin treatment is morally responsible for the death of the man who succumbs to infection with the penicillin-resistant organism.
Alexander Fleming Tweet
The bipartisan PASTEUR Act is the strongest bill ever written to strengthen antibiotic development and use. It will fix our market failures, expand the pipeline for next generation antibiotics, and save lives. We can’t sit on our hands as this public health crisis arrives – we have to act now.
U.S. Senator Michael Bennet Tweet